Tartaglia takes helm at Solstice; AstraZeneca pays Isis $15M milestone; Celsion buys Egen for $14M; Ambrx, Minerva and Ardelyx lay out IPO terms;

@FierceBiotech: Can Orexigen and its partner Takeda escape the weight-drug jinx? Editor's corner | Follow @FierceBiotech

@JohnCFierce: Still trending: Lilly's head-to-head with Victoza raises a red flag for diabetes drug dulaglutide. Article | Follow @JohnCFierce

@DamianFierce: Theme in $AGN's new slides: $VRX's big rush to do a deal is wild suspicious. More | Follow @DamianFierce

@EmilyMFierce: Compound could delay onset of Type 2 diabetes. FierceBiotech Research story | Follow @EmilyMFierce

> RNAi biotech Solstice Biologics, based in San Diego, has wooed Third Rock's Lou Tartaglia to the helm. "Lou brings a wealth of scientific, therapeutic and business development acumen to Solstice from his many successful years shepherding Third Rock portfolio companies," noted Chairman Corey Goodman, a high-profile figure in West Coast biotech circles. "We are delighted that Lou is joining us at this important juncture." Release

> Isis ($ISIS) earned a $15 million milestone from AstraZeneca ($AZN) after the pharma giant launched a Phase I study of the androgen receptor blocker ISIS-ARRx fror prostate cancer. Release

> Celsion Corp. ($CLSN) has struck a deal to buy Egen for $14 million in cash and stock. Egen has a Phase Ib-stage immunotherapy in the clinic. Story

> Ambrx is touting plans to raise $70 million in an IPO, selling 5.4 million shares at $12 to $14 each. Story

> Minerva Neurosciences has laid out plans to sell 5.5 million shares in an IPO designed to raise about $60 million. Story

> Ardelyx set its IPO terms, looking to sell about $50 million worth of shares at $13 to $15 each. Report

> Synthetic Biologics and Enterome Bioscience SA have entered into an agreement to conduct metagenomic research on the effects of beta-lactam antibiotics on the gastrointestinal microflora (microbiome). Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Devicemakers like $MDT, $ABT and $JNJ hold a total of $95 billion offshore--and that's just the tip of the iceberg. Article | Follow @FierceMedDev

@VarunSaxena2: This just in: $MDT will not pursue shareholder complaints against officers, board of directors over Infuse marketing. Filings | Follow @VarunSaxena2

@MichaelGFierce: Mayo Clinic team successfully delivers small molecules to the brain past blood-brain barrier. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: "Hackathons" bring together med tech minds to brainstorm innovative solutions to unmet needs in developing countries. Story from Wired | Follow @EmilyWFierce

> FDA approves Auxogyn embryo test for IVF procedures. Story

> Massachusetts startup develops iOS app for autism. Article

Pharma News

@FiercePharma: Top-read special report Monday: The top 10 pharma companies by 2013 revenue. Feature | Follow @FiercePharma

@TracyStaton: Would you pay $84K for Sovaldi yourself if you had hep C? Check out this discussion. | Follow @TracyStaton

@EricPFierce: New FDA warning letter says Alabama compounder is making sterile drugs in unsanitary facility. More | Follow @EricPFierce

@CarlyHFierce: Allergan spurns Valeant again, but shareholders may have other ideas. Article | Follow @CarlyHFierce

@JustinHFierce: After 7mil US pig deaths from PEDv, Tokyo announces outbreak guidelines on concerns of health-conscious Chinese. Story | Follow @JustinHFierce

> MS docs, activists pressure U.K. cost watchdog to bless Biogen, GW meds. More

> Japanese companies follow Sanofi's lead in shunning Big Pharma M&A trend. Report

> Shaky Dendreon loses its CEO as debt payments loom. News

Pharma Manufacturing News

> FDA says compounder making drugs under unsanitary conditions. More

> Drugmaker will use MIT 3-D printing process to make fast-melting capsules. Item

> More consolidation in the API market as Provence picks up peptidemaker Synprosis. Report

> Illinois man pleads guilty to selling $3M worth of foreign Botox. Story

> Roche's Avastin and MabThera are added to list of those stolen in Italy. Article

> Dr. Reddy's avoids pitfalls of Ranbaxy, Wockhardt by cutting workers out of production. More

Biotech Research News

> Compound could delay onset of Type 2 diabetes. Story

> ImStem therapy reverses multiple sclerosis symptoms in mice. More

> Levels of small molecule in brain may indicate depression. Article

> Report: $4.5B needed for BRAIN project through 2025. Item

> Stem cells transplanted successfully in pigs. Story

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.